Founded Entities

PureTech's Founded Entities are advancing 20 therapeutics and therapeutic candidates, of which two have been cleared for marketing by the U.S. FDA and granted marketing authorization in the European Economic Area, and 13 are clinical stage.

All of these underlying programs and platforms across PureTech's Founded Entities were initially identified or discovered and then advanced by its team through key validation points before being further developed by each respective Founded Entity.

Founded Entities

$1.9B


Investments and Non-Dilutive Funding Raised by Founded Entities Since January 20171

Controlling Interest or Right to Receive Royalties

Advancing a novel category of treatments for weight management and gut related chronic diseases

23.5% Equity plus Royalties
COMMERCIAL
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
Plenity®4,5

Weight management

~150M U.S. (Overweight and obesity)

Commercial
Therapeutic Candidate:
Plenity®
For adolescents

Adolescent weight management

~13.7M U.S.

Pending Discussion with FDA5
Therapeutic Candidate:
GS2003

Weight management in type 2 diabetes (T2D)/prediabetes

~32M U.S. (T2D)
~88M U.S. (Prediabetes)

Clinical Trial Complete
Therapeutic Candidate:
GS3003

Non-alcoholic steatohepatitis/Non-alcoholic fatty liver disease

~80-100M U.S.

Clinical
Therapeutic Candidate:
GS5003

Functional constipation

~35M U.S.

Pivotal

Advancing transformative medicines for people living with psychiatric and neurological conditions

5.5% Equity plus Royalties
PHASE 3
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
KarXT

Schizophrenia

~2.7M U.S.

Phase 3

Alzheimer’s disease psychosis

~3.2M U.S.

Phase 3 Ready

Building a regenerative biology platform for androgenetic alopecia, epithelial aging and other medical indications

76.0% Equity plus Royalties
PHASE 3 READY
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
FOL-004

Androgenetic alopecia

~90M U.S.

Phase 3 Ready

Pioneering a new category of oral therapies based on defined bacterial consortia

41.4% Equity
PHASE 3 READY
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
VE303

Clostridioides difficile

~100-120K/year U.S.

Phase 3 Ready
Therapeutic Candidate:
VE202

Inflammatory bowel disease

~3M U.S.

Phase 2 Ready
Therapeutic Candidate:
VE416

Food allergy

~2.5M U.S. (Peanut allergy)

Phase 1/2
Therapeutic Candidate:
VE800

Solid tumors

>46K/year U.S. (Advanced & metastatic MSS CRC)
>11K/year U.S. (Gastric cancers)
>9K/year U.S. (Melanoma)

Phase 1
Therapeutic Candidate:
VE707
Gram-negative infections
Preclinical

Developing a voice-based technology platform to detect changes of health conditions

44.6% Equity
COMMERCIAL RELEASE
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
Sonde One for Respiratory4
Respiratory risk detection and monitoring app
Commercial Release
Therapeutic Candidate:
Sonde Mental Fitness4

Monitoring vocal features linked to depression, anxiety and cognition

~17M U.S.

Commercial Release

Engineering hydrogels to enable the oral administration of biologics

74.3% Equity
PRECLINICAL

Equity Interest Only

Pioneering the development of cognitive treatments through game-changing technologies

22.3% Equity
COMMERCIAL
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
EndeavorRx®6 (AKL-T01)7

ADHD

~6.4M U.S. (Pediatric ADHD)

Commercial
Therapeutic Candidate:
Cognitive dysfunction in depression

Major depressive disorder

Proof-of-concept completed
Therapeutic Candidate:
Cognitive dysfunction in multiple sclerosis

Multiple sclerosis

Proof-of-concept completed
Therapeutic Candidate:
Attention in autism spectrum disorder

Autism spectrum disorder

Proof-of-concept completed
Therapeutic Candidate:
Post-COVID cognitive dysfunction

Acute cognitive dysfunction

Early scientific and clinical research
Therapeutic Candidate:
Post-ICU cognitive dysfunction
Acute cognitive dysfunction
Early scientific and clinical research
Therapeutic Candidate:
Cancer-related cognitive impairment
Acute cognitive dysfunction
Early scientific and clinical research

Engineering hematopoietic stem cell therapies combined with targeted therapies

8.5% Equity
PHASE 1/2a
Therapeutic Candidate
Initial Indication
Patient Population
Stage of Development
Therapeutic Candidate:
VOR33 (CD33)

Acute myeloid leukemia

~42,500/year U.S., Europe, Japan

Phase 1/2a
Myelodysplastic syndromes, myeloproliferative neoplasms
Preclinical
Therapeutic Candidate:
VCAR33
Bridge-to-transplant AML
Phase 1/2

Note: This figure represents the stage of development for each Founded Entity’s most advanced therapeutic candidate. While PureTech maintains ownership of equity interests in its Founded Entities, the Company does not, in all cases, maintain control over these entities (by virtue of (i) majority voting control and (ii) the right to elect representation to the entities’ board of directors) or direct the management and development efforts for these entities. Consequently, not all such entities are consolidated in the financial statements. Where PureTech maintains control, the entity is referred to as a Controlled Founded Entity in this report and is consolidated in the financial statements. Where PureTech does not maintain control, the entity is referred to as a Non-Controlled Founded Entity in this report and is not consolidated in the financial statements. As of December 31, 2021, Controlled Founded Entities include Follica Incorporated, Vedanta Biosciences, Inc., Sonde Health, Inc. and Entrega, Inc., and Non-Controlled Founded Entities include Gelesis Holdings, Inc., Karuna Therapeutics, Inc., Akili Interactive Labs, Inc., Vor Bio Inc. Relevant ownership interests for Founded Entities were calculated on a partially diluted basis (as opposed to a voting basis) as of December 31, 2021, including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Vor Bio, Karuna and Gelesis ownerships were calculated on a beneficial ownership basis in accordance with SEC rules as of May 6, 2022 and April 30, 2022 and June 7, 2022, respectively. With the exception of Plenity® and EndeavorRx®, candidates are investigational and have not been cleared by the FDA for use in the U.S.

1 Funding figure includes private equity financings, loans and promissory notes, public offerings or grant awards. Funding figure excludes future milestone considerations received in conjunction with partnerships and collaborations. Funding figure does not include Gelesis’ gross proceeds of approximately $105.0 million from its January 2022 SPAC merger.

4 These therapeutic candidates are regulated as devices and their development has been approximately equated to phases of clinical development.

5 Important Safety Information about Plenity®: Patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium dioxide should not take Plenity. To avoid impact on the absorption of medications: For all medications that should be taken with food, take them after starting a meal. For all medications that should be taken without food (on an empty stomach), continue taking on an empty stomach or as recommended by your physician. The overall incidence of side effects with Plenity was no different than placebo. The most common side effects were diarrhea, distended abdomen, infrequent bowel movements, and flatulence. Contact a doctor right away if problems occur. If you have a severe allergic reaction, severe stomach pain, or severe diarrhea, stop using Plenity until you can speak to your doctor. Rx Only. For the safe and proper use of Plenity or more information, talk to a healthcare professional, read the Patient Instructions for Use, or call 1-844-PLENITY.

6 Contingent on FDA review of the research plan.

7 EndeavorRx® is a digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure, Test of Variables of Attention (TOVA®) of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder. There were no serious adverse events; 9.3% of subjects experienced side effects, including frustration, headache, dizziness, emotional reaction, nausea or aggression. EndeavorRx is only available to your patients through a prescription, and is not intended as a stand-alone therapeutic or a substitute for your patient’s medication.

8 Multiple IRBs have determined AKL-T01 to be a non-significant risk device. Akili has obtained IRB approval independently or in collaboration with independent clinical research institutions for all past and ongoing human data collection for clinical research in the United States. We do not control the clinical or regulatory development of Akili’s product candidates. We do not have a direct interest in Akili’s therapeutic or therapeutic candidates. Our interest in Akili’s therapeutic and therapeutic candidates is limited to our equity interest in Akili and any potential appreciation in the value of such equity interest, and we do not control the clinical or regulatory development of Akili’s therapeutic candidates. Akili is well-protected with a robust intellectual property portfolio. Akili was incorporated in February 2012.

Cash at PureTech Parent Level

$321.5m


PureTech Level Pro-forma Cash Reserves3


$120.6m


PureTech Level Cash Reserves as of 31 December 20194

$45m


Cash from KRTX Equity Sale on May 25, 20205

3. PureTech Level Pro-forma Cash Reserves is an alternative performance measure (APM) which includes the PureTech Level Cash Reserves of $120.6 million and the $200.9 million in proceeds from the 22 January 2020 sale of 2.1 million Karuna common shares. PureTech Pro-forma Cash Reserves is therefore considered to be more representative of the Corporate’s cash available for the year 2020 and beyond to advance product candidates within the full breadth of its operations.

4. PureTech Level Cash Reserves represent cash balances and short-term investments held at PureTech Health LLC, PureTech Management, Inc., PureTech Health PLC, PureTech Securities Corporation of $112.0 million for the year ended 2019 and the internal pipeline of $8.6 million for the year ended 2019, all of which are wholly-owned entities of PureTech, excluding cash balances and short-term investments of Controlled Founded Entities. The balance excludes the $200.9 million in proceeds from the 22 January 2020 sale of 2.1 million Karuna common shares.

5. 44.5 million in proceeds from the 22 May 2020 sale of 555.5 thousand Karuna common shares.

Developing breakthrough medicines at PureTech

Collaborative drug discovery based on proprietary biological insights
Rapid & cost-efficient prioritization & validation
Develop internally, partner or spin-out
Collaborative drug discovery based on proprietary biological insights
Rapid & cost-efficient prioritization & validation
Develop internally, partner or spin-out

Relationships with leading pharma companies or their investment arms